Angeliq is a brand name of drospirenone/estradiol, approved by the FDA in the following formulation(s):
ANGELIQ (drospirenone; estradiol - tablet; oral)
Manufacturer: BAYER HLTHCARE
Approval date: September 28, 2005
Strength(s): 0.5MG;1MG [RLD]
Has a generic version of Angeliq been approved?
No. There is currently no therapeutically equivalent version of Angeliq available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Angeliq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDR
Patent 6,933,395
Issued: August 23, 2005
Inventor(s): Mohr; Jörg-Thorsten & Nickisch; Klaus
Assignee(s): Schering AG
Process for the production of drospirenone (6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, DRSP) (1) and 7α-(3-hydroxy-1-propyl)-6β,7β; 15β,16β-dimethylene-5β-androstane-3β,5,17β-triol (ZK 92836) and 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone (ZK 90965) as intermediate products of the process.Patent expiration dates:
- August 11, 2017✓
- August 11, 2017
See also...
- Angeliq Consumer Information (Drugs.com)
- Angeliq Consumer Information (Wolters Kluwer)
- Angeliq Consumer Information (Cerner Multum)
- Angeliq Advanced Consumer Information (Micromedex)
- Drospirenone/Estradiol Consumer Information (Wolters Kluwer)
- Drospirenone and estradiol Consumer Information (Cerner Multum)
- Drospirenone and estradiol Advanced Consumer Information (Micromedex)
No comments:
Post a Comment